<DOC>
	<DOC>NCT00564759</DOC>
	<brief_summary>The aim of the study is to evaluate the side effects and risks after infusion of retroviral gene corrected autologous CD34+ cells of the peripheral blood of chemotherapy conditioned (busulphan)patients with chronic granulomatous disease (CGD). Also gene corrected and functional active granulocytes in the peripheral blood and the engraftment in the bone marrow of the patients will be monitored an documented.</brief_summary>
	<brief_title>Gene Therapy for Chronic Granulomatous Disease</brief_title>
	<detailed_description />
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Granulomatous Disease, Chronic</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<criteria>xlinked Chronic Granulomatous Disease history of lifethreatening severe infections no HLAmatched related or nonrelated donor therapy resistent life threatening infections/organ dysfunction no other treatment options e.g. BMT &lt; 18 years of age HIV infection life expectancy &gt; 2 years infections treatable by conventional therapy (antibiotics, allogeneic granulocytes)</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>CGD</keyword>
</DOC>